Seven patients developed acute hepatitis after receiving Plethoryl for obesity for 4 to 16 weeks. Jaundice was generally associated with or preceded by asthenia, nausea and pruritus. Serum aminotransferase activities were markedly increased whereas alkaline phosphatase and gamma-glutamyltransferase activities were moderately elevated. There was no hepatic failure. In all cases, Plethoryl administration was promptly discontinued. In 6 cases, jaundice disappeared within 2 to 4 weeks, and recovery occurred within 2 to 5 months. In one case, however, jaundice disappeared within 12 weeks and recovery took 10 months.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pathological complete response after chemotherapy in initially unresectable distal cholangiocarcinoma.
Clin J Gastroenterol
December 2024
Department of Diagnostic Pathology, National Hospital Organization Shizuoka Medical Center, 762-1 Nagasawa, Shimizu, Sunto District, Shizuoka, 411-0904, Japan.
Surgical resection is the only curative treatment for cholangiocarcinoma, but it is often diagnosed at advanced stages, making surgical resection infeasible. Recently, the concept of conversion surgery has expanded the indications for surgical treatment, thanks to advancements in both perioperative management and chemotherapy. However, it remains unclear which patients benefit most from this treatment strategy.
View Article and Find Full Text PDFCongenital intrahepatic portosystemic shunt in 27 children: an experience and treatment strategy of a single centre in China.
Front Pediatr
November 2024
Department of General Surgery, Capital Institute of Pediatrics, Beijing, China.
Objective: To evaluate treatment strategies for congenital intrahepatic portosystemic shunt (CIPSS) based on the experience of treating 27 children.
Methods: Between August 2017 and January 2024, our team treated 27 children with CIPSS. Twelve patients underwent surgical ligation of the portosystemic shunt, while 15 patients diagnosed prenatally received conservative treatment without surgery.
Vanishing Bile Duct Syndrome: A Differential Diagnosis for Painless Jaundice.
Cureus
September 2024
Gastroenterology, Surrey and Sussex Healthcare NHS Trust, Redhill, GBR.
Article Synopsis
- Vanishing bile duct syndrome (VBDS) is an acquired liver disease marked by the destruction of intrahepatic bile ducts, often linked to underlying conditions like Hodgkin's lymphoma.
- The case presented involves a 69-year-old woman with symptoms including jaundice and fatigue, leading to a diagnosis of Hodgkin's lymphoma after further medical imaging.
- Despite treatments such as steroids and chemotherapy, the patient ultimately passed away, underscoring the need for increased awareness and consideration of VBDS in diagnosing painless jaundice associated with cholestatic liver dysfunction.
Ultrasound Diagnosis of Bilateral Primary Breast Burkitt Lymphoma in a 28-Year-Old Lactating Patient: A Case Report.
Cancer Manag Res
September 2024
Department of Ultrasound, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, People's Republic of China.
Primary breast Burkitt lymphoma (PB-BL) is an exceedingly rare form of primary breast lymphoma. Ultrasonography is the preferred modality for diagnosing breast diseases; however, the ultrasonic features of Burkitt lymphoma have rarely been reported. Herein, we report a case of ultrasonically diagnosed bilateral PB-BL in a lactating patient and present a literature review.
View Article and Find Full Text PDFEUS-guided hepaticojejunostomy in patients with history of total gastrectomy: a multicenter retrospective feasibility study (with video).
Gastrointest Endosc
January 2025
Endoscopy Unit, Paoli-Calmettes Institute, Marseille, France.
Article Synopsis
- EUS-guided hepaticojejunostomy (EUS-HJS) is a biliary drainage technique for patients with altered anatomy, particularly those who have had total gastrectomy, but data on its effectiveness were previously lacking.
- A retrospective study involving 21 patients found that EUS-HJS achieved 100% technical success and 80% clinical success, helping to alleviate symptoms like jaundice and cholangitis.
- Although the procedure had a 33% adverse event rate, many patients (39%) could resume cancer treatment, and the median survival time after the procedure was 6 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!